FY2025 cost $11.50 of EPS — was it a cycle reset or a permanent rebase?

• The collapse. Diluted EPS came in at $8.92 in FY2025, less than half of FY2024's $20.42, after management's initial $24.50 guide was cut three times — to $19 in July, to roughly $14 in October, and a further miss into year-end. FY2026 is now guided to at least $5, the lowest base since 2018.
• The knife-edge math. The 10-K's own sensitivity table shows one point of Medical Care Ratio is worth roughly $6.20 of EPS. FY2026 guides Medicaid MCR at 92.9% and Medicare MCR at 94.0% — four points above the 88-89% long-term target, with the rate-vs-trend gap already six quarters old.
• What both sides see. The bull reads cyclical — every Medicaid pure-play absorbed the same gap, and Centene took a $6.7B goodwill impairment while Molina took zero. The bear reads structural — management has quietly retired its 13-15% long-term EPS growth framing and refuses to commit to when MCR converges.

Revenue grew; everything below it went the wrong way at once

At a $43B premium base, every 100 basis points of MCR equals roughly $430M of pretax income. The 260bps move alone explains $1.1B of compression — nearly the entire drop in operating income from $1.71B to $781M. Prior-year reserve releases that powered 57% of FY2024 net income collapsed to $98M, and operating cash flow swung negative by $1.18B as Marketplace risk-adjustment payables that had built up since 2020 paid down. ROE fell from a steady 25-32% band to 11.6%. The cushion that flattered 2018-2024 results is gone.

$9B of premium is already pre-loaded, every state license held

• Nearly $9B of incremental premium already on the books. Management quantifies the 2025-vintage award book at almost $9B of incremental annual premium — contracts already won, members already converting. Florida CMS Kids was sole-sourced for 120,000 enrollees at a ~$6B run-rate, and the MMP-to-integrated-D-SNP transition crossed January 1, 2026 across five states for $1.9B.
• A six-year procurement record. Since 2019, Molina has hit a 90% re-procurement win rate on $14B of retained premium and an 80% new-contract win rate on $20B, plus $10B+ of acquired revenue across AgeWell, Cigna Texas, Magellan, Affinity, Bright California and ConnectiCare — with no goodwill impairment booked against any vintage, against Centene's $6.7B writedown in the same cycle.
• Capital architecture intact. All 21 state Medicaid licenses retained through the stress event. Subsidiaries upstreamed $985M to the parent in FY2025 versus $997M in FY2024 — the dividend pipeline did not break. Risk-based capital sits roughly 50% above state minimums, with a $1.25B revolver plus $800M of acquisition-financing capacity running through November 2030.

A $28M CEO sale, a failed pay vote, a covenant cut

• The insider sale six weeks before the cut. On April 30, 2025, CEO Joseph Zubretsky sold 87,500 shares at ~$320 for $28M, without a 10b5-1 plan — the largest insider transaction in the dataset. Twelve weeks later the company cut FY2025 guidance from $24.50 to $19. The 2025 say-on-pay vote then failed for the first time in years, and a board-led roadshow reached holders of 64% of the float to explain it.
• Buyback at the top, then at the bottom. Molina repurchased $500M at ~$294 a share in Q1 FY2025 — underwater at today's $195 — and another $500M at ~$175.50 in Q3. The same management bought 70% more shares per dollar at the trough than at the peak, but the Q1 cohort sits awkwardly next to the CEO's personal sale.
• The lender wrote it in black ink. On February 6, 2026, the credit agreement was amended to cut required interest coverage from 3.00x to 1.75x. S&P downgraded to BB- on April 3, 2026. Parent cash fell from $445M to $223M, days in claims payable dropped from 50 to 44, and a $93M intangibles impairment was booked in Q1 FY2026 against the exiting MAPD product.

From $320 to $129 in twelve months — then a 51% rebound to a ceiling

• The April 22 gap. On Q1 FY2026 earnings, management reaffirmed — rather than raised — the at-least-$5 full-year guide despite a Q1 EPS beat. The stock opened down 29.6%, closed -22.1% from $171.95 to $133.94 on volume 7.9 times normal, then probed a low of $129.41 five sessions later.
• A textbook V, then a ceiling. Eight weeks after the gap the stock had rebuilt to $194.76, within 4.6% of the pre-shock peak. The action since June 8 has tested and failed at $204-205 four separate times, on conspicuously light volume — multiple sub-1M-share sessions on the way up.
• The five-year backdrop. A $100 invested in MOH at year-end 2020 was worth $80 at year-end 2025, against $195 for the S&P 500 and $160 for the managed-care peer group. The 2026 rebound is happening from a multi-year relative low, not a high — and a putative securities class action covering the February 5 to July 23, 2025 window is still live.